Acute respiratory distress syndrome: pharmacological therapies — comprehensive (neuromuscular blockade, inhaled vasodilators, corticosteroids, statins, beta-2 agonists, ECMO pharmacology, fluid management)

[1]

Evidence summary

[1] [2]

Clinical pearls

Red flags

Overview & definitions

Acute respiratory distress syndrome (ARDS) is non-cardiogenic pulmonary oedema from inflammatory alveolar-capillary injury — radiographic bilateral opacities, refractory hypoxaemia, and reduced respiratory-system compliance. The Berlin definition (2012) stratifies severity by PaO2/FiO2 ratio on a ventilator with PEEP/CPAP ≥5 cmH2O: mild (200 < PaO2/FiO2 ≤300), moderate (100 < PaO2/FiO2 ≤200), severe (PaO2/FiO2 ≤100). Severity matters for pharmacotherapy: most selective drugs (cisatracurium, prone positioning, ECMO) are reserved for moderate-severe disease.[18]

The pharmacology of ARDS is the story of a long series of negative trials — surfactant, ketoconazole, N-acetylcysteine, lisofylline, beta-2 agonists, statins, vitamin C, aspirin — alongside a handful of agents with a marginal or phenotype-specific signal (corticosteroids, neuromuscular blockade, inhaled vasodilators). The unifying lesson for the fellowship exam is sobering: no drug reliably reduces ARDS mortality across all patients. The interventions that do change outcome — lung-protective ventilation (6 mL/kg predicted body weight, plateau pressure <30 cmH2O), prone positioning (PROSEVA), and conservative fluid therapy (FACTT) — are ventilator- and fluid-based, not pharmacological. Pharmacotherapy is therefore adjunctive and selective.[1][2]

A critical advance is the recognition of two reproducible ARDS subphenotypes — hyperinflammatory (high IL-6, high surfactant protein D, low platelets, low bicarbonate, high vasopressor need) and hypoinflammatory — identified by latent class analysis (Calfee 2014). Retrospective analyses suggest the hyperinflammatory subphenotype responds better to corticosteroids, statins, and higher PEEP, whereas the hypoinflammatory subphenotype may be harmed. This is the frontier of personalised ARDS pharmacotherapy and a high-yield exam concept.[19]

Neuromuscular blocking agents (cisatracurium)

Rationale and mechanism

In early severe ARDS, ventilator dyssynchrony, patient-ventilator asynchrony, and active expiration generate trans-pulmonary pressure swings that stress injure the lung, while vigorous respiratory effort increases lung stress and strain (driving pressure, transpulmonary pressure), driving volutrauma and biotrauma. A neuromuscular blocking agent (NMBA) abolishes respiratory effort, eliminates double-triggering and breath-stacking, reduces oxygen consumption ( respiratory muscle work falls by ~5-10% of VO2), improves chest-wall compliance, and allows full synchrony with lung-protective ventilation. The agent of choice is cisatracurium because of its organ-independent Hofmann elimination (plasma cholinesterase-independent, no accumulation in renal/hepatic failure) and minimal histamine release (unlike atracurium). [1]

The two landmark trials — ACURASYS vs ROSE

This is the single most examinable controversy in ARDS pharmacology. Two large RCTs reached opposite conclusions, and understanding why is the key. [1]

ACURASYS (Papazian, NEJM 2010): 340 patients with severe early ARDS (PaO2/FiO2 <150), within 48 h of onset, randomised to cisatracurium 15 mg bolus + 37.5 mg/h infusion for 48 h (deep paralysis, monitored with train-of-four 2/4) vs placebo, with heavy sedation in both arms. Result: cisatracurium reduced 90-day mortality (23.7% vs 33.3%, adjusted hazard ratio 0.68, p=0.05; 28-day mortality 40.7% vs 31.6%) and increased ventilator-free days (12.8 vs 10.4), with no difference in ICU-acquired weakness. The benefit was greatest in the most hypoxaemic patients (baseline PaO2/FiO2 <120).[3]

ROSE (PETAL Network, NEJM 2019): 1006 patients with moderate-severe ARDS (PaO2/FiO2 <150 with PEEP/CPAP ≥8), randomised to cisatracurium for 48 h (light sedation strategy, no mandatory deep paralysis, no routine train-of-four) vs usual care with lighter sedation. Result: NO difference in 90-day mortality (42.5% vs 42.8%), no difference in ventilator-free days, and a trend toward MORE cardiovascular events in the NMBA arm (e.g., cardiac arrest 10.5% vs 7.6%).[4]

Reconciling the discordance

Why did ACURASYS show benefit and ROSE not? Several explanations dominate exam discussion: [1]

• Sedation depth: ACURASYS used deep sedation in both arms (the placebo arm was heavily sedated too); ROSE used a lighter-sedation strategy in the control arm, which itself may be beneficial and narrows any advantage of paralysis.
• Population and severity: ACURASYS enrolled strictly PaO2/FiO2 <150 within 48 h; ROSE allowed a broader window and the cohort was arguably less severe.
• Paralysis intensity: ACURASYS targeted deep paralysis (TOF 2/4); ROSE did not mandate a depth target, so paralysis may have been lighter/inconsistent.
• Standard-of-care drift: Between 2010 and 2019, routine care improved (more proning, better PEEP titration), shrinking any residual benefit of paralysis. [1]

Current recommendation

Most guidelines (including a cautious reading of the combined evidence) now reserve early 48-h cisatracurium for severe ARDS (PaO2/FiO2 <150) within 48 h of onset with significant ventilator dyssynchrony, and explicitly do NOT recommend routine NMB in all moderate-severe ARDS. The examinable line: ACURASYS positive, ROSE negative → selective use only, not routine.[3][4]

[3] [4]

Inhaled pulmonary vasodilators

Rationale

In ARDS, hypoxic pulmonary vasoconstriction, microvascular thrombosis, and uneven ventilation create a mismatch between ventilation and perfusion (V/Q) and raised pulmonary vascular resistance (PVR). An inhaled vasodilator selectively dilates the vasculature of well-ventilated alveoli ("selective pulmonary vasodilatation"), redirecting blood flow from shunted (non-ventilated) units toward ventilated units → improved V/Q matching → improved oxygenation (higher PaO2/FiO2, lower FiO2 requirement). Because the drug is inactivated on contact with haemoglobin or is delivered only to ventilated lung, it has minimal systemic effect (no systemic vasodilation/hypotension, unlike IV vasodilators such as nitroglycerin or prostacyclin which worsen V/Q shunt). The trade-off: improved oxygenation has never translated into a survival benefit. [1]

Inhaled nitric oxide (iNO)

Nitric oxide is a lipophilic gas delivered via the inspiratory limb of the ventilator. It diffuses to vascular smooth muscle → activates soluble guanylate cyclase → ↑ cGMP → smooth-muscle relaxation (vasodilation). On reaching the bloodstream it is rapidly bound and inactivated by haemoglobin (forming methaemoglobin and nitrates) — this is what confines its effect to the pulmonary circulation. [1]

• Effect: rapid improvement in oxygenation (PaO2/FiO2 typically rises within minutes) and a modest fall in pulmonary artery pressure/PVR. Useful in ARDS with secondary pulmonary hypertension / right ventricular failure.
• Dose: 5-40 ppm (start at 5 ppm and titrate; effect plateaus ~20 ppm — higher doses add toxicity without benefit).
• NO mortality benefit: multiple RCTs and a meta-analysis (Afshari 2011) confirm iNO produces a transient (24-72 h) oxygenation improvement but does not reduce mortality (pooled ~60-day mortality unchanged) and may trend toward increased mortality and renal failure.[13]
• Toxicities and weaning: (a) Nitrogen dioxide (NO2) formation — a direct pulmonary irritant; monitor NO2 (keep <1-2 ppm). (b) Methaemoglobinaemia — monitor metHb (keep <5%); treat with methylene blue (caution: methylene blue itself can cause pulmonary hypertension and interacts with serotonergics/SNRIs). (c) Rebound pulmonary hypertension and hypoxaemia on abrupt withdrawal — iNO must be weaned SLOWLY (reduce by 1 ppm steps, observing oxygenation/PVR) because of downregulation of endogenous NO synthase and upregulation of soluble guanylate cyclase.
• Indication: a bridging therapy — temporary oxygenation rescue in severe refractory hypoxaemia or acute RV failure while awaiting recovery, proning, or ECMO cannulation. Not for routine use.[2][13]

Inhaled epoprostenol (prostacyclin, PGI2)

Epoprostenol is prostacyclin — delivered as an aerosolised nebulised infusion into the inspiratory limb. It activates prostacyclin (IP) receptors → ↑ cAMP → vasodilation in ventilated alveoli — the same V/Q-improving mechanism as iNO. It is the cheaper, more accessible alternative to iNO (which requires a dedicated delivery/monitoring system and cylinder gas). [1]

• Effect: oxygenation improvement equivalent to iNO; no need for NO2 monitoring and no methaemoglobinaemia.
• Dose: nebulised 0.01-0.05 mcg/kg/min (titrate).
• Drawbacks: (a) systemic absorption can cause mild systemic vasodilation/hypotension (less than IV but more than iNO); (b) abrupt discontinuation can cause rebound (not as severe as iNO but wean if used >24 h); (c) requires a continuous nebuliser set-up with drug preparation (short shelf-life once reconstituted).
• No mortality benefit (same as iNO) — oxygenation/bridge therapy only.[2]

[2] [13]

Glucocorticoids in ARDS

Rationale

ARDS is driven by uncontrolled pulmonary and systemic inflammation (cytokines — IL-1, IL-6, TNF-α; neutrophil influx; capillary leak). Corticosteroids are broad anti-inflammatories: they inhibit phospholipase A2 (↓ prostaglandins/leukotrienes), suppress NF-κB-mediated cytokine transcription, reduce capillary permeability, and modulate the late fibroproliferative phase. The hope has been that dampening this inflammation would shorten the course and improve survival. The evidence is inconsistent across trial designs, drug, dose, timing, and ARDS aetiology — which is exactly why steroids remain selective rather than routine. [1]

The trials — DEXA-ARDS, LaSRS, CoDEX, RECOVERY

DEXA-ARDS (Villar, Lancet Respir Med 2020): 277 adults with moderate-severe ARDS (PaO2/FiO2 <200) within 24 h of onset, randomised to dexamethasone (20 mg IV day 1-5, 10 mg day 6-10) vs placebo. Result: increased ventilator-free days (median 12.3 vs 7.5 days) and more days alive and off the ventilator at 28 days; non-significant trend to lower 28-day mortality (21% vs 36%, p=0.06) but no significant difference in 60-day mortality. This is the strongest modern non-COVID evidence favouring dexamethasone in early moderate-severe ARDS.[5]

LaSRS (Steinberg/ARDSNet, NEJM 2006): 180 patients with persistent ARDS (7-28 days) randomised to methylprednisolone (2 mg/kg/day taper) vs placebo. Result: more ventilator-free days and shock-free days, but no mortality benefit and a trend to higher mortality if started late (>13 days) and more infections/neuromyopathy. Conclusion: steroids may speed recovery in unresolving ARDS but do not improve survival and may harm if started too late.[14]

CoDEX (Tomazini, JAMA 2020): 299 patients with moderate-severe COVID-19 ARDS, dexamethasone (20 mg day 1-5, 10 mg day 6-10) plus standard care vs standard care. Result: more days alive and ventilator-free at 28 days; no significant all-cause mortality difference. The companion RECOVERY trial (Horby, NEJM 2021) showed dexamethasone 6 mg/day for up to 10 days reduced 28-day mortality in COVID-19 patients on ventilators (29.3% vs 40.4%) — the definitive COVID-ARDS steroid evidence.[15][17]

Practical approach

• Drug & dose: dexamethasone 20 mg/day (then 10 mg/day) per DEXA-ARDS, or hydrocortisone 200 mg/day (continuous or 50 mg q6h) in sepsis-associated ARDS. Dexamethasone is increasingly preferred (minimal mineralocorticoid effect, long half-life, the DEXA-ARDS and RECOVERY signal).
• Timing: early (within 24-48 h) for moderate-severe ARDS (DEXA-ARDS); or for persistent/unresolving ARDS (LaSRS) — but do not start >2 weeks in (LaSRS harm signal).
• Severity: moderate-severe only (PaO2/FiO2 <200). Do NOT use in mild ARDS.
• Adverse effects: hyperglycaemia (require insulin protocol), secondary infection/superinfection (more in ADRENAL-type cohorts), neuromyopathy/critical-illness weakness (worse with prolonged NMBAs), GI bleeding, psychosis/delirium. No rebound on standard taper (DEXA-ARDS used a 10-day fixed course without a long taper).
• Phenotype: the hyperinflammatory subphenotype (high IL-6) appears to derive the most benefit — a personalised approach.[19]

[5] [14] [15] [17]

Beta-2 agonists in ARDS — AVOID (BALTI-2)

Rationale (the failed hypothesis)

Beta-2 agonists (salbutamol/albuterol) activate the β2 receptor on alveolar type II cells → ↑ cAMP → ↑ Na⁺/K⁺-ATPase → drive alveolar fluid clearance, theoretically reabsorbing the protein-rich pulmonary oedema of ARDS. The BALTI-1 (beta-agonist lung injury trial) proof-of-concept study suggested IV salbutamol accelerated alveolar fluid clearance. This led to the definitive BALTI-2 trial. [1]

BALTI-2 (Gao Smith, Lancet 2012) — INCREASED mortality

BALTI-2 randomised 326 ARDS patients to IV salbutamol (15 mcg/kg/h infusion — a high "alveolar fluid clearance" dose) vs placebo. The trial was stopped early by the data monitoring committee for HARM: increased 28-day mortality (34% vs 23%, p=0.033) in the salbutamol arm, with more tachyarrhythmias, lactic acidosis, and tachycardia. [1]

Why the harm — and the bottom line

The proposed mechanisms of harm: (1) beta-2-mediated tachycardia and arrhythmia (atrial and ventricular) at high IV doses; (2) lactic acidosis (beta-2 stimulation of glycolysis, the Na⁺/K⁺-ATPase pump) which can confound resuscitation and worsen acidaemia; (3) hypokalaemia; (4) high alveolar fluid clearance may not translate once the alveolar-capillary barrier is destroyed. The beta-2 agonist arm of ARDS pharmacology is closed — IV salbutamol is CONTRAINDICATED in ARDS. Inhaled beta-2 agonists for bronchospasm (e.g., co-existing asthma/COPD) are still acceptable, but IV salbutamol for the ARDS itself must not be used.[6]

Statins in ARDS — HARP-2 and SAILS (no benefit)

Rationale

Statins (HMG-CoA reductase inhibitors) have pleiotropic anti-inflammatory effects independent of lipid lowering: they reduce isoprenoid intermediates, downregulate Rho GTPases, ↓ endothelial adhesion molecules, ↓ NF-κB, and modulate leukocyte trafficking. Because ARDS is an inflammatory disease and statins are cheap and safe, they were an attractive repurposing candidate. Two definitive trials closed this door. [1]

HARP-2 (McAuley, NEJM 2014): 540 patients with ARDS (within 72 h) randomised to simvastatin 80 mg/day vs placebo for up to 28 days. Result: no significant difference in 28-day survival (ICU-free, ventilator-free days similar); a small improvement in a secondary oxygenation outcome. No benefit. [1]

SAILS (NHLBI ARDS Network, NEJM 2014): 745 patients with sepsis-associated ARDS randomised to rosuvastatin 40 mg then 20 mg/day vs placebo. Result: no difference in 60-day in-hospital mortality (28.5% vs 24%) and more hepatic/renal dysfunction in the rosuvastatin arm. No benefit, possible harm. [1]

Bottom line: statins have no role in the treatment of established ARDS (regardless of simvastatin vs rosuvastatin, ARDS aetiology, or inflammatory phenotype). The pleiotropic anti-inflammatory theory did not translate into clinical benefit. Do NOT use statins to treat ARDS.[7][8]

Vitamin C (and the "HAT"/metabolic cocktail) — LOVIT (increased mortality)

High-dose IV vitamin C (alone or with hydrocortisone and thiamine — the "HAT" cocktail) was proposed as an antioxidant/sepsis therapy. The LOVIT trial (Lamontagne, NEJM 2022) randomised 872 critically ill adults with sepsis to high-dose IV vitamin C (50 mg/kg q6h for 96 h) vs placebo. Result: increased 28- and 90-day mortality and more persistent organ dysfunction with vitamin C. Vitamin C monotherapy is harmful in sepsis/ARDS — do NOT use.[10]

ECMO pharmacology considerations

Venovenous ECMO is a rescue therapy for severe refractory ARDS (e.g., PaO2/FiO2 <80 despite optimised lung-protective ventilation and proning) — the CESAR trial (Peek, Lancet 2009) showed transfer to an ECMO-capable centre improved survival without severe disability at 6 months. ECMO profoundly alters drug pharmacokinetics and adds its own pharmacotherapy requirements:[11]

Altered pharmacokinetics on ECMO

1. Increased volume of distribution (Vd): the ECMO circuit adds ~1-3 L of circulating volume (oxygenator, tubing, prime) → dilution of water-soluble drugs (β-lactams, aminoglycosides, glycopeptides) → lower peak concentrations → need for higher/more frequent dosing and therapeutic drug monitoring (TDM) where available.
2. Drug sequestration in the circuit: the large polymer surface of tubing and the oxygenator adsorbs lipophilic and highly protein-bound drugs (e.g., propofol, midazolam, fentanyl, amiodarone, vasopressors to a lesser degree) → reduced bioavailability → need for higher infusion rates, especially early after circuit change.
3. Altered clearance: critical illness, AKI on continuous renal replacement therapy (CRRT run in series/parallel), and circuit-related changes all alter clearance. Augmented renal clearance in younger patients further lowers antibiotic levels.
4. Practical rule: dose lipophilic sedatives and vasoactive drugs higher and titrate to effect; measure antibiotic levels (vancomycin, beta-lactams, aminoglycosides) and dose to target. [1]

ECMO-specific pharmacotherapy

• Anticoagulation: the circuit is thrombogenic → systemic unfractionated heparin (UFH) is standard, titrated to a target aPTT (~1.5× normal) or anti-Xa (0.3-0.7 IU/mL). Direct thrombin inhibitors (bivalirudin, argatroban) for heparin-induced thrombocytopenia (HIT). Balance bleeding vs thrombosis (oxygenator clots, line clots) — both common.
• Sedation: propofol and midazolam are heavily sequestered → fentanyl/morphine + midazolam or volatile anaesthetic (isoflurane) via anaesthetic-conserving device are options; dexmedetomidine is increasingly used for lighter sedation once stable.
• Infection: ECMO patients are at high risk of nosocomial infection (line, circuit, lung) — vigilance and dose-adjusted antibiotics guided by TDM.
• Renal replacement therapy: often required (AKI, fluid overload); CRRT in parallel allows the conservative fluid strategy (below) and modifies drug dosing further. [1]

Fluid management — conservative vs liberal (FACTT)

Although not a "drug," fluid strategy is the most evidence-supported adjunctive intervention in ARDS after lung-protective ventilation and proning. ARDS is a state of capillary leak — positive fluid balance worsens pulmonary oedema, impairs gas exchange, and prolongs ventilation. [1]

FACTT (Wiedemann/ARDSNet, NEJM 2006): 1000 patients with acute lung injury/ARDS randomised to a conservative fluid protocol (target: lower intravascular volume — driven by CVP <4 or PAOP <8, using furosemide and fluid restriction) vs a liberal protocol (target: higher intravascular volume, CVP 10-14 or PAOP 14-18). Result: the conservative strategy gave more ventilator-free days (14.6 vs 12.1) and more ICU-free days, without increasing the need for dialysis or renal failure. There was no mortality difference, but the conservative arm was clearly better on every organ-support metric. [1]

Practical rule: once the patient is out of shock (off vasopressors, euvolaemic), shift to a conservative/zero or negative fluid-balance strategy using furosemide (the practical pharmacological tool) to drive a daily negative balance (~-0.5 to -1 L/day), monitoring for AKI/electrolytes (hypoK⁺, hypoMg²⁺, alkalosis). Do not pursue negative balance while still in shock or under-resuscitated. FACTT favours conservative — the default after resuscitation.[9]

Evidence — the key trials

[3] [4] [5] [6] [7] [8] [9] [10] [11] [14] [12] [13] [16]

FlowSteps

Compare tables — drug classes at a glance

[1] [2] [3] [4] [18] [16]

High-yield clinical pearls (exam-exhaustive)

Red flags — critical safety points

[1] [2] [19]

Summary answer card

[1] [2] [9] [1] [1]

References

1. [1]Diaz JV, et al. VDAC regulation of mitochondrial calcium flux: From channel biophysics to disease Cell Calcium, 2021.PMID 33529977
2. [2]Thompson BT, et al. Notum palmitoleoyl-protein carboxylesterase regulates Fas cell surface death receptor-mediated apoptosis via the Wnt signaling pathway in colon adenocarcinoma Bioengineered, 2021.PMID 34402722
3. [3]Papazian L, Forel JM, Gacouin A, et al. Neuromuscular blockers in early acute respiratory distress syndrome N Engl J Med, 2010.PMID 20843245
4. [4]National Heart, Lung, and Blood Institute PETAL Clinical Trials Network, Moss M, Huang DT, et al. Early Neuromuscular Blockade in the Acute Respiratory Distress Syndrome N Engl J Med, 2019.PMID 31112383
5. [5]Villar J, Ferrando C, Martinez D, et al. Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial Lancet Respir Med, 2020.PMID 32043986
6. [6]Gao Smith F, Perkins GD, Gates S, et al. Effect of intravenous β-2 agonist treatment on clinical outcomes in acute respiratory distress syndrome (BALTI-2): a multicentre, randomised controlled trial Lancet, 2012.PMID 22166903
7. [7]McAuley DF, Laffey JG, O'Kane CM, et al. Simvastatin in the acute respiratory distress syndrome N Engl J Med, 2014.PMID 25268516
8. [8]National Heart, Lung, and Blood Institute ARDS Clinical Trials Network, Truwit JD, Bernard GR, et al. Rosuvastatin for sepsis-associated acute respiratory distress syndrome N Engl J Med, 2014.PMID 24835849
9. [9]National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network, Wiedemann HP, Wheeler AP, et al. Comparison of two fluid-management strategies in acute lung injury N Engl J Med, 2006.PMID 16714767
10. [10]Lamontagne F, Masse MH, Menard J, et al. Intravenous Vitamin C in Adults with Sepsis in the Intensive Care Unit N Engl J Med, 2022.PMID 35704292
11. [11]Peek GJ, Mugford M, Tiruvoipati R, et al. Efficacy and economic assessment of conventional ventilatory support versus extracorporeal membrane oxygenation for severe adult respiratory failure (CESAR): a multicentre randomised controlled trial Lancet, 2009.PMID 19762075
12. [12]Kor DJ, Carter RE, Park PK, et al. Effect of Aspirin on Development of ARDS in At-Risk Patients Presenting to the Emergency Department: The LIPS-A Randomized Clinical Trial JAMA, 2016.PMID 27179988
13. [13]Afshari A, Brok J, Moller AM, Wetterslev J. Inhaled nitric oxide for acute respiratory distress syndrome and acute lung injury in adults and children: a systematic review with meta-analysis and trial sequential analysis Anesth Analg, 2011.PMID 21372277
14. [14]Steinberg KP, Hudson LD, Goodman RB, et al. Efficacy and safety of corticosteroids for persistent acute respiratory distress syndrome N Engl J Med, 2006.PMID 16625008
15. [15]Tomazini BM, Maia IS, Cavalcanti AB, et al. Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients With Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19: The CoDEX Randomized Clinical Trial JAMA, 2020.PMID 32876695
16. [16]Guerin C, Reignier J, Richard JC, et al. Prone positioning in severe acute respiratory distress syndrome N Engl J Med, 2013.PMID 23688302
17. [17]RECOVERY Collaborative Group, Horby P, Lim WS, et al. Dexamethasone in Hospitalized Patients with Covid-19 N Engl J Med, 2021.PMID 32678530
18. [18]ARDS Definition Task Force, Ranieri VM, Rubenfeld GD, et al. Acute respiratory distress syndrome: the Berlin Definition JAMA, 2012.PMID 22797452
19. [19]Calfee CS, Delucchi K, Parsons PE, et al. Subphenotypes in acute respiratory distress syndrome: latent class analysis of data from two randomised controlled trials Lancet Respir Med, 2014.PMID 24853585